Desmopressin Research: What 5,888 Studies Show (2026) | RetatrutideCompare

Desmopressin — 5,888 studies indexed on PubMed. Selective V2 receptor agonist (renal antidiuresis) with minimal pressor effect; releases von Willebrand factor and Factor VIII from endothelium. Half-life: ~3 hours. FDA status: FDA-approved (1978).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Desmopressin?

There are approximately 5,888 studies indexed on PubMed that mention Desmopressin (DDAVP, Stimate), based on a search last updated 2026-06-18.

Is Desmopressin FDA-approved?

FDA status: FDA-approved (1978).

How does Desmopressin work?

Selective V2 receptor agonist (renal antidiuresis) with minimal pressor effect; releases von Willebrand factor and Factor VIII from endothelium.

Reference facts

Also known as: DDAVP, Stimate, 1-deamino-8-D-arginine vasopressin
Category: Hormonal & Pituitary
Mechanism of action: Selective V2 receptor agonist (renal antidiuresis) with minimal pressor effect; releases von Willebrand factor and Factor VIII from endothelium.
Targets: V2R
Indications under research or approved: Central diabetes insipidus, Nocturnal enuresis, Mild hemophilia A and von Willebrand disease
Regulatory status (reference entry): FDA-approved (1978)
Half-life: ~3 hours
Sequence notes: Synthetic AVP analog: 1-desamino-cysteine and D-Arg at position 8, retaining Cys1-Cys6 disulfide.
Molecular weight (Da): 1069
First reported: 1967

Primary References

Robertson et al., NEJM 1973 (DDAVP)

Explore research articles about Desmopressin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.